Archive
All News
Every briefing, headline, and filing we've published, newest first.
The WeekBioPharma Dive ↗
The occurrence of "neuropsychiatric" adverse events in testing fueled investor doubts about a drug the FDA is …
The WeekBioPharma Dive ↗
The latest installment in BioPharma Dive's new visualization-focused series features a stock sell-off that con…
The WeekPharmaVoice ↗
Yale researchers untangled norovirus RNA and Evvy just pulled in $40 million for precision medicine in women's…
The WeekPharmaceutical Technology ↗
With a $3.95m price tag, Fayuvi - a one-time gene therapy - is one of the most expensive drugs on the market.…
The WeekPharmaVoice ↗
As the orexin competition heats up in the neuroscience space, Harmony Biosciences is developing an early-stage…
The WeekFiercePharma ↗
Ultragenyx scored a belated regulatory win with FDA approval for a first-in-disease gene therapy, giving the c…
The WeekFierceBiotech ↗
Bristol Myers Squibb has axed the degrader-antibody conjugate it bought from Orum Therapeutics for $100 millio…
The WeekBriefing
North Immunology plans to go public through a reverse merger as it advances an atopic dermatitis drug toward t…
The WeekDrug Channels ↗
Today's guest post comes from Tom Traylor, Senior Vice President of Pharmacy Operations at CareMetx. Tom exami…
The WeekPharmaceutical Technology ↗
WuXi XDC Cayman is to provide Ona Therapeutics with an exclusive global licence to its WuXiTecan-2 platform to…
The WeekSTAT News ↗
It wasn't until he started medical school, Brian Zhang writes, that he realized 'Asian glow' from drinking was…
The WeekBioPharma Dive ↗
Nearly a dozen biotechnology firms have matched or raised more than $300 million in their initial public offer…
The WeekPharmaVoice ↗
A confirmatory late-stage study is now also underway for what the startup is positioning as, potentially, the …
The WeekPharmaVoice ↗
Fresh filings and older proposals reveal different tests of clinical evidence, financing needs and readiness f…
The WeekFiercePharma ↗
After a 2024 rebuff, AstraZeneca and Daiichi Sankyo's star antibody drug conjugate Enhertu has been deemed cos…
The WeekFierceBiotech ↗
A phase 2b study of Longeveron's stem cell therapy in a pediatric heart disease has missed its primary endpoin…
The WeekBriefing
KFF’s latest AI-in-health-care episode zeroed in on a basic problem: the FDA’s 1976 device framework was built…
The WeekSTAT News ↗
Why a biotech hedge fund decided to build from the ground up a new company to develop a better, long-acting an…
The WeekBioPharma Dive ↗
Through a research deal worth up to $1 billion, Dualitas will sift through more than 300,000 possible bispecif…
The WeekPharmaceutical Technology ↗
Japan's Ministry of Health, Labour and Welfare has approved Viatris' Wakix for EDS related to OSAS and for nar…
The WeekPharmaVoice ↗
Small patient communities face repeated demands for samples, data and time. The Speak Foundation's founder exp…
The WeekFiercePharma ↗
The rare disease biotech announced that it would discontinue efforts to develop Voxzogo for children with Noon…
The WeekFierceBiotech ↗
After teasing a new initiative to speed up early-stage clinical trials over the summer, the FDA today opened a…
The WeekBriefing
Jaguar LAA, a newly formed medtech, said it acquired assets from Johnson & Johnson’s Laminar AFib device p…
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.